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The uses of genetic sequences to inform, enable or create products or services for human biomedicine are 
substantially different from their uses in crop-based agriculture.
In human medicine, a successful new prod-uct or process can create a strong economic 
incentive to pay whatever it takes to be healthy, 
with the potential profit in conventional busi-
ness models correspondingly very high. This 
huge value-capture opportunity is used to 
justify high-capital and high-risk innovation 
and investment, with corresponding patent-
ing strategies. For instance, inventions that 
enable the development of small-molecule 
pharmaceuticals that associate with protein 
or nucleotide targets (such as receptors) or of 
direct biological interventions such as vaccines, 
RNA or protein-based therapeutics are attrac-
tive and potentially lucrative commercial pur-
suits. Similarly, diagnostics that detect allelic 
variation in human genes or proteins or detect 
and discriminate between genetic variants of 
human pathogens or beneficials have high 
potential value.
In plant-based agriculture, however, the 
unit value of a single plant or even a cultivar 
is generally very low, and profit margins for 
most commodity crops are modest. With 
little new acreage to cultivate, and with so 
much of broad-acre crops already biotech 
enhanced, many markets are nearly saturated, 
and farmers simply cannot pay much more 
for next-generation technologies. With cur-
rent business models, therefore, and such low-
margin targets, the scope of patent claiming of 
new inventions may need to cover an entire 
variety, species, very broad-use cases or new 
functionalities that enable potential new crop 
uses or novel crop-management tools such as 
herbicides or insecticides.
For each of these uses, patenting of both 
nucleotide and amino acid sequences may 
be important but will be done with different 
strategies and economies in mind. We have 
previously described1 the scope and type 
of patenting that disclosed and/or claimed 
genetic sequences on the human genome. 
Here, we explore what similarities and dif-
ferences may emerge in patent use and strat-
egies, and map patent-disclosed sequences 
onto three important plant genomes: maize 
(corn), rice and soybean. We focus on those 
referenced in the granted patent claims to 
compare their uses to the approach used in 
human gene patenting.
Mapping biological sequences disclosed 
in patents using a 95% homology thresh-
old shows 2.8 million patent sequences 
each for the maize and soybean genomes 
and 2.5 million on the rice genome, versus 
31 million patent sequences mapped on the 
human genome as of 13 November 2014. We 
chose the 95% homology threshold to maxi-
mize the likelihood that allelic differences 
between a patent-disclosed sequence and a 
related canonical reference genome would 
Figure 1  Mapped patent sequences on maize, rice and soybean genomes were compared to those 
mapped on the human genome on the basis of various similarity (S) and query length coverage (C) 
rates. Sequences are displayed according to their disclosure in patent document type. A, sequences 
disclosed in patent applications; AC, sequences referenced in the claims of patent applications; 
G, sequences disclosed in granted patents; GC, sequences referenced in the claims of granted patents.
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(http://plants.ensembl.org/Oryza_sativa/
Info/Annotation) and Glycine max (soy-
bean) assembly glyma1 V1.0.21 (http://plants.
ensembl.org/Glycine_max/Info/Annotation/)
using the Burrows–Wheeler Aligner suite4. As 
discussed previously, many patent claims pro-
vide rights over sequences with as little as 70% 
identity to a disclosed sequence; we therefore 
selected a range of homology thresholds to 
determine alignment and location of candidate 
sequences on the crop genomes. Homology 
thresholds were specified by two metrics: 
patent sequence similarity and coverage in 
proportion to the sequence length. The simi-
larity rate (S) reflects the number of matching 
nucleotides between the patent sequence and 
the reference genome, and the sequence cov-
erage (C) reflects the proportion of the patent 
sequence that was included in the alignment. 
Because of the high repeat rate in the sequence 
listing corpus, a nonredundant data set of pat-
ent sequences was initially used for the map-
ping and redundancy was later reincorporated 
in the tool.
Under the most stringent conditions, 
S100C100 (100% similarity and 100% cover-
age rate)—wherein the mapped sequence is 
Association for Molecular Pathology v. Myriad 
Genetics, Inc.2 and Mayo Collaborative Services 
v. Prometheus Labs, Inc.3 and their potential 
impact on the various industries and the pub-
lic interest.
Mapping of plant genomes
To compare gene patent practice and its extent 
across plant and human genomes, we enriched 
our PatSeq toolkit with plant genome maps 
for maize, rice and soybean (http://www.lens.
org/lens/bio/patseqexplorer - pse/zea_mays/
latest). The selected field crops are economi-
cally important, grown widely and have 
diverse uses and distinct (and different) busi-
ness models associated with their commercial 
use. Moreover, we updated the previously 
published human genome map1 and created 
PatSeq Analyzer, a stand-alone tool wherein 
users can now search by sequence identifier 
number within each genome and download 
the sequences freely.
We mapped patent-disclosed sequences 
onto the following reference genomes: Zea 
mays (maize) assembly AGPv3.21 (http://
plants.ensembl.org/Zea_mays/Info/Index), 
Oryza sativa Japonica (rice) RGSP-1.0.21 
not exclude the sequence as a likely homolog 
of that reference sequence.
Whereas 130,000 of the mapped human 
sequences were referenced in patent claims, 
fewer than 11,000 from each of the plant 
genomes were referenced. Of these, we deter-
mined that more than 80% overlapped with 
(i.e., were either sourced from or equivalent 
to homologs in) other genomes, including 
the human genome, and often consisted of 
short nucleotide sequences. In comparison, 
only 12% of the human nucleotide sequences 
overlapped with those of plant genomes. We 
identified 3,956 sequences overlapping across 
all organisms examined (maize, rice, soybean 
and human) and subjected their corresponding 
763 patents to further characterization, includ-
ing claim analysis.
In addition to a high level of sequence redun-
dancy in the overlapping data set, we highlight 
three different claim types wherein the use of 
a short sequence could be problematic and 
could, hypothetically, raise infringement con-
cerns. We review each type and provide some 
examples. We conclude by discussing the 
introduced changes to gene patent practice 
after the recent US Supreme Court decisions in 
Figure 2  Unique and overlapped patent sequences that are referenced in the claims of granted patents, depicted on the basis of sequence type and length. 
The holdings of mapped sequence entries with 95% homology threshold against each of the four genomes are contained in color-coded ellipses, and areas of 
overlap are shaded. (a) Mapped patent nucleotide sequence entries. (b) Peptide patent sequence entries. (c–e) Mapped patent nucleotide sequence entries 
of 1–50 bp (c), 50–5,000 bp (d) and >5,000 bp (e).
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6,787,133 and 7,067,283. The sequence is 
used in a method for obtaining mammalian 
telomerase protein, in a method for identify-
ing regulators of telomerase activity and in 
producing a compound that regulates telom-
erase activity, respectively. Finally, the same 
sequence also appears as SEQ ID 3 in US pat-
ent 7,781,163 as part of a compound forming 
a G-quadruplex structure and as SEQ ID 2 in 
US patent 8,053,422 in a method for treat-
ing, preventing or delaying development of 
papilloma (Supplementary Table 2 provides 
further detail).
In a single instance, we found a sequence 
entry, SEQ ID 1, referenced in the claims of 
a plant (maize)- and Bacteroides forsythusa 
(a periodontal pathogen)-related patent (US 
patents 5,710,367 and 5,789,174, respec-
tively), and in both patents the sequence was 
used as a primer in method claim.
Third, we checked for other potential 
infringement issues based on the use of 
sequences in claims related to both humans 
and plants. Relying on US classification 
codes, we screened the corresponding patent 
documents and selected relevant claims for 
manual analysis. We found at least three pat-
terns of claims that may be problematic when 
a short sequence is referenced in the claims:
1. Wherein the applicant claims exclusively 
the use of the sequence as isolated poly-
nucleotide, oligonucleotide or nucleic acid, 
etc., without specifying the host, modified 
structure or function of the sequence. In 
principle, the patent holder can potentially 
use such claim to exclude any other use of 
the sequence raising infringement concerns 
(Table 1 shows some examples).
2. Wherein the applicant claims nonexclu-
sively the use of the overlapped sequence in 
a core technology applicable at the research 
phase. As the technology has potential to be 
applied to all sequence-based inventions, 
such as “a kit for gene expression” (US pat-
ent 6,221,600) or “a screening method for 
genomic polynucleotide library” (US patent 
8,846,403), the patent holder can monopolize 
the use of such a technology at the research 
phase across all fields of use and potentially 
delay or block improvements.
3. Wherein the applicant uses overlapped and 
conserved short sequences to target a specific 
technique that alters the genomic makeup of 
both human and plant components (US pat-
ents 6,936,467; 7,226,785 and 7,258,854), and 
thus claiming broadly based on the use of that 
sequence across many species. A single pat-
ent rights holder can then potentially block 
Sorting first by the unique fingerprint 
available for each sequence entry, we found 
that 39% of the sequences were redundant. 
Redundancy ranged from a simple duplica-
tion of the sequence entry within a docu-
ment or between two related documents to 
referencing the same sequence up to 26 times 
across three documents (US patent 7,709,196, 
sequence identifiers (SEQ IDs) 33; 37; 39; 45; 
105; 145; 149; 151; 157, US patent 8,293,517, 
SEQ IDs 18; 22; 28; 94; 134; 138; 140; 146 
and US patent 8,367,319, SEQ IDs 33; 37; 
39; 45; 105; 145; 149; 151; 157. These results 
suggest that if the sequence entry is relevant 
to the invention, applicants will use it in an 
original patent claim and probably in any of 
the improved or follow-on inventions, and, 
in a few cases, different applicants may do 
so as well.
Second, by aligning the overlapped data 
with that of human genome data ana-
lyzed previously1, we confirmed that single 
sequence entries were sometimes referenced 
in the claims of multiple patents. For exam-
ple, SEQ ID 13 of US patent 7,781,182 is a 
76-amino acid (76-aa) sequence that is ref-
erenced in the claims of that patent as part 
of an assay for ubiquitin ligase activity. The 
same sequence is referenced as SEQ ID 1 in 
the claims of US patent 8,518,660 as part of a 
di-ubiquitin used in an assay for measuring 
the isopeptidase activity of a deubiquitinase. 
Finally, it is referenced as SEQ ID 15 in the 
claims of US patents 8,592,179; 8,790,895 
as being used in methods for producing 
modified ubiquitin proteins and preparing a 
modified ubiquitin polypeptide, respectively, 
and of US patent 8,791,238 as the reference 
sequence for a modified ubiquitin protein.
According to US Patent and Trademark 
Office (USPTO) records, the first two patents 
mentioned above are assigned to different 
companies, but the final three are all assigned 
to the same company (Supplementary 
Table 1 provides further detail).
Similarly, SEQ ID 5 of US patent 5,489,508 
is an 18 bp–nucleic acid sequence that is ref-
erenced as a substrate for telomerase primer 
extension used in a method for detecting 
cancer in humans. It is also referenced in 
related US patent 5,645,986 as a telomerase 
substrate used as part of a method for screen-
ing for telomerase inhibitors. According to 
USPTO records, the first patent is assigned 
to the Regents of the University of Texas, and 
the second is assigned to the Regents of the 
University of California.
The same sequence, referenced as SEQ ID 
6, also appears in the claims of three patents 
that USPTO records show as being assigned 
to Geron Corporation: US patents 6,545,133; 
identical to that of the reference genome—
we matched 2.8 million sequences on 
maize and soybean genomes and 2.5 mil-
lion sequences on rice genome, in contrast 
to 31 million sequences mapped against the 
human genome, with the percentage of patent 
sequences referenced in the claims ranging 
0.2–0.3% among the various genomes (Fig. 1).
These correspond to sequence listing 
entries after the reintroduction of the redun-
dancy in the corpus. During this exercise, we 
observed that less than 30% of the mapped 
sequences against the crop genomes were 
declared as the corresponding plant species, 
whereas 71% of mapped sequences against 
the human genome were declared in the orig-
inal patent documents as human. However, 
when we relaxed the homology thresholds 
from 100% to 95%, we saw a boost in the 
matching rate of the declared plant species 
to more than 60% in the mapped data set, 
indicating that a homology threshold of 
S95C95 would be more appropriate for fur-
ther analyses.
By 13 November 2014, we had 9,986; 7,838 
and 10,634 sequence listing entries mapped 
onto the maize, rice and soybean genomes, 
respectively, under the 95% homology thresh-
old. These sequences were referenced in the 
claims of 2,241; 1,758 and 1,889 patents 
granted, most of which were US patents, and 
about 30% of which were lapsed or expired.
Analysis of the overlapped sequences 
among plant and human genomes
A substantive overlap was observed between 
the plant genome–mapped sequences and 
those mapped against the human genome. We 
performed an overlap analysis on all mapped 
sequence entries across the four genomes, 
focusing only on those referenced in the 
claims of granted patents (GC category). The 
analysis confirmed the presence of patent 
sequence overlap across all four genomes (Fig. 
2). We selected the 3,956 sequence entries that 
overlapped across all four organisms for fur-
ther characterization. Most (3,947) are nucle-
otides (DNA, RNA and cDNA) (Fig. 2a); nine 
are peptide sequences (Fig. 2b).
Upon splitting the nucleotide database 
on sequence length into three categories 
(1–50 bp, 50–5,000 bp and >5,000 bp), we 
found that almost all overlapped sequence 
entries were 1–50 bp in length (Fig. 2c), 
except for three overlapped sequences of the 
second category (Fig. 2d). No overlapped 
sequences were observed in the third category 
(Fig. 2e). To further characterize the short 
sequences, mainly the 3,947 nucleotide and 
the nine peptide sequences, we extracted and 
examined their associated metadata.
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during prosecution. For example, below we 
compare an early version of claim 1 of the 
application that issued as US patent 8,772,024 
on 8 July 2014 with a later version.
Before March 2014, claim 1 read: “An iso-
lated nucleic acid molecule selected from the 
group consisting of: a nucleotide sequence 
consisting of the polynucleotide sequence of 
SEQ ID 1 or 2; wherein the sequence initiates 
transcription in a plant cell.”
After March 2014, the claim read: “An iso-
lated nucleic acid molecule selected from the 
group consisting of: a nucleotide sequence 
consisting of the polynucleotide sequence of 
SEQ ID 1 or 2; wherein the sequence initiates 
transcription in a plant cell, and wherein said 
nucleic acid molecule is linked to a heterologous 
nucleic acid molecule [italics added].”
The italicized clause was added by the 
USPTO examiner specifically for the purpose 
of complying with Myriad, and the applicants 
consented to this amendment, but this part was 
omitted from the claims as published. A notice 
of correction needs to be filed to have this fixed. 
Claim 1 as amended complies with Myriad.
Another example is US patent 8,692,076 
issued on 8 April 2014. In the application 
before Myriad, claim 1 read: “A DNA molecule 
comprising a sequence which is, or is comple-
mentary to, a DNA sequence selected from the 
groups consisting of SEQ ID NO: 1 and SEQ ID 
NO: 2.” Claim 2 read: “An isolated DNA mol-
ecule for use as a DNA probe that is diagnostic 
for soybean event MON87769 DNA, compris-
ing at least 11 contiguous nucleotides of SEQ 
ID NO: 1, or complement thereof.”
After Myriad, the claims were as follows. 
Claim 1: “A DNA molecule comprising SEQ ID 
NO: 1 or SEQ ID NO: 2, the DNA molecule fur-
ther comprising a nucleic acid molecule encod-
ing Primula juliae delta 6 desaturase, or the full 
complement thereof [italics added].” Claim 2: 
“The DNA molecule of Claim 1, comprising 
SEQ ID NO: 6, or a full complement thereof 
[italics added].”
The introduced changes, italicized here, were 
added by the USPTO examiner specifically for 
the purpose of complying with Myriad and 
written description requirements. In the appli-
cation, claims 1 and 2 were “broadly drawn” 
to cover “any DNA molecule which comprises 
any DNA nucleotide residue which is comple-
mentary to only a single nucleic acid residue of 
SEQ ID NO: 1 or SEQ ID NO: 2.” The amended 
claims had a narrower scope. The applicants 
consented to these amendments.
Conclusions
As in the human genome map, the three 
plant genome maps reveal physical locations 
of patent sequences that were either sourced 
and anxiety from national and international 
groups7–10. For example, the Association for 
Molecular Pathology commended the USPTO 
for implementing the court decisions; con-
firmed that threshold determinations are for 
all claims involving natural laws, principles, 
phenomena and products; and recommended 
that the guidance provide an even clearer 
qualitative standard of “markedly different” 
to maintain patent ineligibility for homolo-
gous sequences and any “claimed associa-
tions between genetic mutations and their 
relationships to medically relevant physical or 
physiologic effects.”11 But the Association of 
University Technology Managers, the Council 
on Governmental Relations, the Association 
of American Universities and the Association 
of Public and Land-grant Universities chal-
lenged the legality of expanding court deci-
sions to all claims and expressed strong 
concerns about the proposed legal standard 
and its potential negative impact on pending 
or existing university patents on natural prod-
ucts12. Law associations and professionals in 
the industry sector raised similar concerns 
about the applicability of Myriad and Mayo 
to other claims.
As these fierce legal debates go on, patent 
examiners have, since March 2014 and in 
some cases since the Myriad decision in June 
2013, been narrowing some pending applica-
tion claims that involve nucleotide sequences 
further experimentation and follow-on inno-
vations in a cumulative-type innovation.
Referenced sequences that are 
plant related
To examine mapped sequences that are refer-
enced in plant-related inventions, we first had 
to hand-edit each of the three plant genome 
data sets—in particular granted patents that 
reference these mapped sequences in the claims 
as their ‘declared species’ metadata information 
was often lacking or inadequate—disambiguate 
applicant and owner names and analyze them 
within the context of other intellectual prop-
erty (IP) rights.
State of affairs after Myriad
After decades of allowing patent protection for 
a broad range of biotechnology tools and mate-
rials—including genetically modified cells, 
plants and animals—the US Supreme Court 
recently narrowed the scope of patent protec-
tion in its Myriad and Mayo decisions by hold-
ing that naturally occurring DNA sequences 
are unpatentable, as are laws of nature and 
abstract mental processes.
On 4 March 2014, the USPTO proposed a 
new procedure to apply the court decisions 
and invited members of the public to com-
ment6. The published reactions encompassed 
divergent arguments for or against the guid-
ance and revealed old, unsettled tensions 
Table 1  Examples of potentially broad sequence claims
US patent number 
and SEQ ID Selected claims
Patent 8,785,611; 
SEQ ID 31
Claim 1: “An isolated polynucleotide sequence comprising at least two mRNA 
translational enhancer elements (TEE), wherein at least one TEE consists of a full-
length sequence that is selected from the group consisting of 5ʹ-CGCGGCTGA-3ʹ 
(SEQ ID NO: 31), 5ʹ-AGCCGCCGCA-3ʹ (SEQ ID NO: 34) and 5ʹ-ACGCCGCCGA-3ʹ 
(SEQ ID 35).”
Patent 8,288,355; 
SEQ ID 27
Claim 1: “An isolated polynucleotide of 15 to 49 bases in length comprising 
at least 15 contiguous bases in the nucleotide sequence of SEQ ID NO:26 that 
include the nucleotide sequence of SEQ ID NO:27.”
Patent 7,807,817; 
SEQ ID 151
Claim 2: “An isolated catalytic DNA molecule having sequence-specific endo-
nuclease activity, wherein said molecule comprises a conserved core, wherein said 
conserved core comprises the sequence CCGAGCCGGACGA (SEQ ID NO:151), or 
wherein said conserved core comprises the sequence CCGAGCCGGACGA (SEQ ID 
NO:151) having one to three residues substituted by G, A, T, or C.”
Patent 7,456,273; 
SEQ ID 40
Claim 1: “An isolated transcriptional regulatory element selected from any of SEQ 
ID NOS: 40.” 
Claim 2: “A recombinant nucleic acid molecule comprising a plurality of opera-
tively linked isolated transcriptional regulatory elements of claim 1.” 
Claim 3: “A kit, comprising an isolated transcriptional regulatory element accord-
ing to claim 1.” 
Claim 4: “The kit of claim 3, further comprising a vector for containing the regula-
tory element.” 
Claim 5: “The kit of claim 3, comprising a plurality of isolated transcriptional 
regulatory elements.”
Patent 5,707,803; 
SEQ ID 1
Claim 1: “An isolated DNA molecule 13 to 200 nucleotides in length compris-
ing at least one regulatory element that binds to an activated transcriptional 
regulatory protein, said regulatory element comprising a nucleotide sequence 
of TATTCCTGGAAGT (SEQ ID NO: 1), TATTCCGGTAAGT (SEQ ID NO: 2), 
TCTTCCTGTAAGT (SEQ ID NO: 3), TATTCCCGTAAGT (SEQ ID NO: 6), or 
TATTCCTATAAGT (SEQ ID NO: 7).”
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filing 1983), and granted Monsanto, its owner, 
exclusive rights on this technology until about 
year 2029 (https://www.lens.org/lens/patent/
US_8273954_B1). This is one of the broad 
patents on “Agrobacterium-mediated trans-
formation methods” that—after a series of 
lawsuits, oppositions, mergers and acquisi-
tions—asserted Monsanto’s dominance in the 
genetically modified crop business14.
Although narrowing the scope of gene pat-
entability is commendable and may address 
some of these issues, more can be done to 
stimulate biological innovation. Further work 
is under way to uncover plant-related inven-
tions based on these plant genome maps, 
analyze broadly the patent claims and explore 
their ownership and its impact in the context 
of other plant intellectual properties.
Note: Any Supplementary Information and Source Data 
files are available in the online version of the paper 
(doi:10.1038/nbt.3364).
pany used the same DNA primers for poly-
merase chain reaction–based genetic testing.
Two other types of short sequence–based 
claims may be problematic: those extending 
to core research technologies and those tar-
geting wide fields of use (plant, fungi, bac-
teria and animal). Although not involving 
specific sequences, the best example of the 
former are US patents 4,816,567; 6,331,415; 
and 7,923,221, known collectively as the 
Cabilly patents after one of the inventors13. 
The Cabilly patents are directed to key steps 
in the manufacture of therapeutic antibodies 
and as such have been immensely valuable to 
their owner, Genentech, as well as the subject 
of numerous lawsuits between Genentech and 
various other biotechnology companies. An 
example of the latter is US patent 8,273,954 
directed to Agrobacterium transformation of 
dicotyledonous plant cells. The patent was 
issued in 2012 after almost 30 years (priority 
from the corresponding genome or derived 
from other organisms but showed homol-
ogy during the mapping process (Fig. 3). 
Having such maps can be extremely useful in 
precision plant breeding, especially as addi-
tional tracks of various markers are linked. 
In addition to tracking inheritance patterns 
of important traits, particularly quantitative 
trait loci, trends of gene expression or regula-
tion in commercial traits can be now visual-
ized across these three genome maps using 
the PatSeq toolkit.
Although far from exhaustive, our claim 
analysis of the overlapping sequences between 
human and plant genomes shows that such 
sequences are referenced relatively frequently 
in patent claims, often without explicit refer-
ence to a host, function or chemical modifica-
tions. Such practice could, in principle, raise 
infringement concerns—for example, if an 
agribusiness and a medical diagnostic com-
Figure 3  A screenshot of the three plant genome maps each compared to that of human in PatSeq Explorer. Users can access and navigate mapped 
sequences on the basis of sequence type (nucleotide or peptide) and/or location in a patent document (referenced in patent claims or not) and download 
relevant patent sequences freely.
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